# Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

> **NCT04925284** · PHASE1 · COMPLETED · sponsor: **Exelixis** · enrollment: 269 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Cervical Cancer
- SCCHN
- Pancreatic Cancer
- Esophageal SCC
- Metastatic Castration-resistant Prostate Cancer
- Triple Negative Breast Cancer
- Hormone Receptor-positive Breast Cancer
- Epithelial Ovarian Cancer
- Endometrial Cancer
- Tissue Factor-Expressing Solid Tumors

## Interventions

- **DRUG:** XB002
- **DRUG:** Nivolumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04925284
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-07
- **Primary completion:** 2025-03-10
- **Final completion:** 2025-03-10
- **Target enrollment:** 269 (ACTUAL)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04925284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04925284, "Study of XB002 in Subjects With Solid Tumors (JEWEL-101)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04925284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*